Bioteck manufactures biological medical devices, using original patented processes through a continuous research and development process in the field of biotechnology. Its mission is to simplify the surgical phase and improve the quality of life of the patient.
Becoming the reference manufacturer of regenerative solutions and technical-surgical applications the less invasive possible.
Professionalism, innovation, intellectual curiosity, courage, trust, reliability, integrity, passion.
Bioteck begins to produce medical devices of equine origin thanks to the application of an innovative enzymatic system for the elimination of antigenic components, potentially applicable to any type of heterologous tissue.
The corporate structure changes and with new shareholders investments in research, development and communication are growing.
Bioteck obtains ISO 9001 and ISO 13485 certifications.
The new Processing Laboratory is set up in Turin. Over 2000 square meters dedicated to research, development and production thanks to the 250 square meters occupied by clean rooms.
Bioteck is moving towards new types of products such as bone pastes and the innovative and unique Flex series: bone grafts that, initially rigid, are made flexible through a particular process of electrolytic demineralization .
The Vicenza office is greatly expanded.
The Heart® pericardium membrane is launched and successfully used in orthopedics, dentistry and neurosurgery. In the same year, some devices produced by the company obtained ANVISA certification from Brazil.
The enzymatic process for the elimination of antigens is optimized, patented and registered with the name of Zymo-Teck®.
Bioteck exports its devices to over 50 countries. The brand new Multifunctional Center for Production, Research and Development is inaugurated in Turin.
Bioteck launches the open doors program: 750 square meters on 3 floors specially set up for the organization of events and training courses for customers and business partners.
In the same year Bioteck differentiates the offer of regenerative solutions available to surgeons by launching 3 Synt®, its first synthetic line based on beta-tricalcium phosphate, on the market.
Awayr®, the innovative perfusion system capable of saturating any type of porous biomaterial with biological fluids or solutions, is launched: an effective response to the risk of air remaining in traditionally soaked biomaterials.
In parallel, the offer of biomaterials for regenerative surgery is enriched with the launch of the new edition of Calcitos®, a slow-absorbing equine bone substitute obtained by heat treatment.
The Bioteck Academy was born, an ideal meeting point between research and development, basic research, training activities and high-level clinical and scientific collaborations.
Bioteck is present in over 70 countries, where is supported by qualified and prestigious commercial partners.